Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei-Ching Liang

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2018
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid LeukemiaBing Zheng, Shang-Fan Yu, Geoffrey Del Rosario, et al.
Cancer Cell|January 16, 2007
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growthQi Pan, Yvan Chanthery, Wei-Ching Liang, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2020
Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophyIrene Tom, Victoria C Pham, Kenneth J Katschke, et al.
Molecular Cancer Therapeutics|February 4, 2021
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian CancerAmy A Lo, Jennifer Johnston, Ji Li, et al.
Molecular Cancer Therapeutics|September 16, 2008
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptakeYonglei Shang, Yifan Mao, Jennifer Batson, et al.
Cancer Cell|April 9, 2008
Blocking neuropilin-2 function inhibits tumor cell metastasisMaresa Caunt, Judy Mak, Wei-Ching Liang, et al.
Molecular Pharmaceutics|April 9, 2015
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancerSteven R Leong, Wei-Ching Liang, Yan Wu, et al.
Immunity|February 13, 2020
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMPYi Zhou, Mingjian Fei, Gu Zhang, et al.
Science Advances|May 22, 2026
Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicityYvonne T Kschonsak, Wei-Ching Liang, Joyce Chan, et al.
Science Translational Medicine|August 5, 2021
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesisTianhe Sun, Zhiyu Huang, Wei-Ching Liang, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2018
An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid LeukemiaBing Zheng, Shang-Fan Yu, Geoffrey Del Rosario, et al.
Cancer Cell|January 16, 2007
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growthQi Pan, Yvan Chanthery, Wei-Ching Liang, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 30, 2020
Development of a therapeutic anti-HtrA1 antibody and the identification of DKK3 as a pharmacodynamic biomarker in geographic atrophyIrene Tom, Victoria C Pham, Kenneth J Katschke, et al.
Molecular Cancer Therapeutics|February 4, 2021
Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian CancerAmy A Lo, Jennifer Johnston, Ji Li, et al.
Molecular Cancer Therapeutics|September 16, 2008
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptakeYonglei Shang, Yifan Mao, Jennifer Batson, et al.
Cancer Cell|April 9, 2008
Blocking neuropilin-2 function inhibits tumor cell metastasisMaresa Caunt, Judy Mak, Wei-Ching Liang, et al.
Molecular Pharmaceutics|April 9, 2015
An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancerSteven R Leong, Wei-Ching Liang, Yan Wu, et al.
Immunity|February 13, 2020
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMPYi Zhou, Mingjian Fei, Gu Zhang, et al.
Science Advances|May 22, 2026
Tumor-targeted bispecific antibodies effectively inhibit oncogenic pathways while minimizing toxicityYvonne T Kschonsak, Wei-Ching Liang, Joyce Chan, et al.
Science Translational Medicine|August 5, 2021
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesisTianhe Sun, Zhiyu Huang, Wei-Ching Liang, et al.
Pageof 5